Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | CDC14B | O60729 | 1/20 | 0.31 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22818459 | 0.96 | ALOX5 (0.41) | ALOX5GGPS1CDC14BCDC14APTGES2 | |
| SCHEMBL22817773 | 0.96 | ALOX5 (0.41) | ALOX5GGPS1CDC14BCDC14APTGES2 | |
| SCHEMBL22818481 | 0.93 | ALOX5 (0.36) | ALOX5CDC14BCDC14APRKDC | |
| SCHEMBL22817974 | 0.93 | ALOX5 (0.36) | ALOX5CDC14BCDC14APRKDC | |
| SCHEMBL22817759 | 0.93 | ALOX5 (0.36) | ALOX5CDC14BCDC14APRKDC | |
| SCHEMBL22818148 | 0.93 | ALOX5 (0.36) | ALOX5GGPS1CDC14BCDC14APTGES2 | |
| SCHEMBL22818152 | 0.93 | ALOX5 (0.44) | ALOX5GGPS1CDC14BCDC14APTGES2 | |
| SCHEMBL22818150 | 0.92 | ALOX5 (0.45) | ALOX5GGPS1CDC14BCDC14APTGES2 | |
| SCHEMBL22817758 | 0.92 | ALOX5 (0.38) | ALOX5GGPS1CDC14BCDC14APRKDC | |
| SCHEMBL22817760 | 0.92 | ALOX5 (0.38) | ALOX5GGPS1CDC14BCDC14APRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11812623-B2 | Hetero-cyclic compound and organic light emitting device using the same | LT MATERIALS CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11812623-B2 | Hetero-cyclic compound and organic light emitting device using the same | LT MATERIALS CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20200403157-A1 | HETERO-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | LT MATERIALS CO., LTD. (KR) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11812623-B2 | Hetero-cyclic compound and organic light emitting device using the same | CRY1, CRY2, PER2 | ALOX5 1385/4885GGPS1 598/4885CDC14B 589/4885 |
| US-20200403157-A1 | HETERO-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | CRY1, CRY2, PER2 | ALOX5 1385/4885GGPS1 598/4885CDC14B 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.